Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip·2010·New England Journal of Medicine
DOI 10.1056/nejmoa1009744

Cited by (752)

Items 701–752 of 752

  1. Serum Levels of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), and Cardiac Function in Patients with Unstable Angina Pectoris
    Manyun Long, Lang Li · 2020 · Medical Science Monitor
  2. Lipoprotein Disorders
    Sekar Kathiresan, Daniel James Rader · 2012 · Elsevier eBooks
  3. Lipoprotein (a): Principles from Bench to Bedside
    Marlys L. Koschinsky, Michael B. Boffa · 2020 · Contemporary cardiology
  4. New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
    Ahmed Bakillah · 2019 · MDPI eBooks
  5. "The higher the better" seems to be no longer true for HDL-cholesterol
    Hana Rosolová · 2018 · Vnitřní lékařství
  6. Innovative Lipid Biomarkers and Long-Term Outcomes
    Josephine L.C. Anderson · 2021 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  7. Preventive Cardiology
    Temilolu Aje, Michael J. Miller · 2013 · Springer eBooks
  8. HDL function metrics and clinical outcomes in prospective cohort studies
    Congzhuo Jia · 2022
  9. Frontmatter
    Anatol Kontush, M. John Chapman · 2011 · Wiley eBooks
  10. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
    Bernard J. Gersh · 2011 · Yearbook of Cardiology
  11. 心臓病学研究の進歩(循環器学2010年の進歩)
    渡辺 昌文, 永井 良三 · 2011 · Journal of JCS Cardiologists
  12. Principles of Primary and Secondary Prevention of Cardiovascular Disease
    Danny J. Eapen, Nima Ghasemzadeh, Naveen Bellam, Neal Kumar Bhatia, Kiran Valiani, Jia Shen, Richard J. VanDam, Peter Flueckiger, Daniel L. Molloy, Jenna Kay et al. · 2014 · Springer eBooks
  13. Familial hyperlipidaemia
    Nazish Khan, Helen Williams · 2015 · British Journal of Cardiac Nursing
  14. Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, United States, November 13-17, 2010)
    Pablo Avanzas y, Antoni Bayés‐Genís, Leopoldo Pérez de Isla, Juan Manuel Sanchís, Magda Heras · 2011 · Revista Española de Cardiología (English Edition)
  15. 4th Asian Preventive Cardiology And Cardiac Rehabilitation Conference
    2012 · Journal of the Hong Kong College of Cardiology
  16. COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF MODERN MEANS OF HYPERCHOLESTEROLEMIA CORRECTION
    Y. H. Hajiyeva · 2022 · World of Medicine and Biology
  17. Almanac 2013: Stable coronary artery disease the national society journals present selected research that has driven recent advances in clinical cardiology
    Adam Timmis · 2014 · Srce i krvni sudovi
  18. Evolving Therapeutic Targets
    Stephen James Nicholls, Adam J. Nelson · 2023 · Elsevier eBooks
  19. Invasive Imaging Modalities and Atherosclerosis
    Stephen James Nicholls, Steven E. Nissen · 2015 · Elsevier eBooks
  20. Evolving Targets of Therapy
    Philip J. Barter, Kerry‐Anne Rye · 2015 · Elsevier eBooks
  21. Unraveling the Mystery: How High Density Lipoprotein ‘Good’ Cholesterol Goes ‘Bad’?
    Oğuz Arslantürk, Ahmet Aydın, Fatih Gümüş, Kübra Sarıkaya Aydın, Naciye Dilara Zeybek, Hande Canpınar, Murat Güvener · 2024 · Medical Journal of Western Black Sea
  22. Novel Lipid-Lowering Agents
    Zahid Ahmad, Abhimanyu Garg · 2015 · Contemporary Endocrinology
  23. Additional file 1 of High-density lipoprotein cholesterol efflux capacity and incidence of coronary artery disease and cardiovascular mortality: a systematic review and meta-analysis
    Cheng, Wenke, Maciej Rosołowski, Boettner, Julia, Steffen Desch, Alexander Jobs, Thiele, Holger, Buettner, Petra · 2022 · Figshare
  24. Additional file 1 of Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study
    Sébastien Tanaka, Jules Stern, Donia Bouzid, Tiphaine Robert, Monique Dehoux, Aurélie Snauwaert, Nathalie Zappella, Maxime Cournot, Brice Lortat‐Jacob, Pascal Augustin et al. · 2021 · Figshare
  25. Additional file 4 of Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study
    Sébastien Tanaka, Jules Stern, Donia Bouzid, Tiphaine Robert, Monique Dehoux, Aurélie Snauwaert, Nathalie Zappella, Maxime Cournot, Brice Lortat‐Jacob, Pascal Augustin et al. · 2021 · Figshare
  26. Additional file 3 of Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study
    Sébastien Tanaka, Jules Stern, Donia Bouzid, Tiphaine Robert, Monique Dehoux, Aurélie Snauwaert, Nathalie Zappella, Maxime Cournot, Brice Lortat‐Jacob, Pascal Augustin et al. · 2021 · Figshare
  27. Additional file 2 of Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study
    Sébastien Tanaka, Jules Stern, Donia Bouzid, Tiphaine Robert, Monique Dehoux, Aurélie Snauwaert, Nathalie Zappella, Maxime Cournot, Brice Lortat‐Jacob, Pascal Augustin et al. · 2021 · Figshare
  28. Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?
    Charles L. Shear, Michael H. Davidson, Marc Ditmarsch, John J.P. Kastelein, Michael J. Szarek · 2026 · American Heart Journal Plus Cardiology Research and Practice
  29. HDL and Cardiovascular Disease: Mechanisms, Therapeutic Advances, and Challenges
    Koushik Sen, Abhinaba Sinha · 2026 · Proceedings of the Zoological Society
  30. Cholesterol: an ancient ally or modern menace?
    Ismael Luna-Reyes, Stephanie Villa-Jaimes, Sandra Calixto-Tlacomulco, Eréndira Guadalupe Pérez-Hernández, Danai Montalvan‐Sorrosa, Juan Pablo Reyes‐Grajeda, Jaime Mas‐Oliva · 2026 · Royal Society Open Science
  31. Remodelage de la paroi artérielle : étude des aspects de destruction et de reconstruction
    Fabrice M. Schneider · 2011 · theses.fr (ABES)
  32. De la dose à l'effet clinique : utilisation de la modélisation dans les différentes étapes du processus de prédiction du critère clinique : Exemple avec un nouveau médicament en prévention secondaire de la morbidité-mortalité cardiovasculaire
    Florence Hourcade‐Potelleret · 2012 · theses.fr (ABES)
  33. Le petit déjeuner standardisé. Un outil diagnostique du statut glycémique et des modifications cardiovasculaires postprandiales ? : Comparaison vs la charge en glucose ; et explorations cardiovasculaires sous saxagliptine vs placebo chez des patients intolérants au glucose
    Amel Rezki · 2019 · theses.fr (ABES)
  34. Identification de nouveaux acteurs du métabolisme des HDL : impact sur les maladies cardiovasculaires
    Lise M. Hardy · 2019 · theses.fr (ABES)
  35. Lipoprotéines de haute densité (HDL). Implications diagnostiques et thérapeutiques au cours de la COVID 19.
    Floran Bègue · 2024 · theses.fr (ABES)
  36. Novel Aromatic Sulfonimides With Antidyslipidemic Activity: Facile Synthesis, In Silico, and In Vivo Studies
    Laurance M. S. Bourghli, Amneh Shtaiwi, Osama H. Abusara, Mohammad Alwahsh, Mirna W. Awadallah, Sameer Al-Kouz, Aya Hasan, Rahaf S. Alshehada · 2026 · ChemistrySelect
  37. Structural optimization of cholesteryl ester transfer protein inhibitors: From early scaffolds to advanced clinical candidates
    Mahla Abdollahzadeh, Mahin Ramezani, Mahdi Hatamipour · 2026 · European Journal of Medicinal Chemistry
  38. Phospholipids that Plug the Pores of Cholesteryl Ester Transfer Protein Control Its Triglyceride Transfer
    Sukriti Sacher, Praveen Singh, Abhishek Mukherjee, Akash Kumar Bhaskar, Kausik Chakraborty, Laurent Counillon, Shantanu Sengupta, Mallorie Poët, Arjun Ray · 2026 · Computational and Structural Biotechnology Journal
  39. Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis and network meta-regression
    Ibrahim Khalil, M Rafiqul Islam, Sunjida Amin Promi, Arindam Das Joy, Md Abu Sayed, Durjoy Acharjee, Ali Saad Al‐Shammari, Mohd Turzo Rahman, Sakib Abrar, Ta-Seen Bin Jamil et al. · 2026 · Medicine
  40. Biology of HDL: From Structural Heterogeneity to Dysfunctional Remodeling in Cardiovascular Disease and Comorbidities
    Y N Cai, Kehan Li, Huibo Ma, Jianqiang Wu, Yuehong Zheng · 2026 · Antioxidants
  41. Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis
    Maciej Banach, Vikash Jaiswal, Song Peng Ang, Hanna Ahuja, Muhammad Saad Khan, Arman Qamar, Agata Magdalena Bielecka-Dabrowa, Leandro N. Slipczuk, Seth S Martin, Filippo Crea · 2026 · European Heart Journal - Cardiovascular Pharmacotherapy
  42. BindingDB Entry 50014676: Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
    BindingDB · 2022 · UC San Diego
  43. BindingDB Entry 50047345: Design, synthesis and biological evaluation of N,N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor.
    BindingDB · 2017 · UC San Diego
  44. BindingDB Entry 50033609: Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
    BindingDB · 2012 · UC San Diego
  45. BindingDB Entry 50040316: Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors.
    BindingDB · 2013 · UC San Diego
  46. BindingDB Entry 50043863: Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.
    BindingDB · 2014 · UC San Diego
  47. BindingDB Entry 50034533: Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein.
    BindingDB · 2012 · UC San Diego
  48. BindingDB Entry 50034344: SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
    BindingDB · 2012 · UC San Diego
  49. BindingDB Entry 50044760: Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    BindingDB · 2016 · UC San Diego
  50. BindingDB Entry 50047141: Discovery of novel N,N-3-phenyl-3-benzylaminopropionanilides as potent inhibitors of cholesteryl ester transfer protein in vivo.
    BindingDB · 2017 · UC San Diego
  51. Perspectives on Cholesterol Guidelines
    Scott M. Grundy · 2015 · Contemporary Endocrinology
  52. Липопротеид (а) как единственный фактор риска у молодого мужчины с инфарктом миокарда А. Л. Бурдейная, М. В. Ежов, Ю. Г. Матчин, И. А. Алексеева, О. А. Комар, В. В. Кухарчук ФГБУ «Российский кардиологический научно-производственный комплекс МЗ РФ», Москва
    A.L. Burdeynaya, Ежов Марат Владиславович, Ю Г Матчин, И. А. Алексеева, О. А. Комар, Valery V. Kukharchuk · 2014 · CyberLeninK (CyberLeninka)